

Oludotun Adebayo Phillips

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9586457/publications.pdf>

Version: 2024-02-01

47
papers

726
citations

623734

14
h-index

552781

26
g-index

52
all docs

52
docs citations

52
times ranked

818
citing authors

#	ARTICLE	IF	CITATIONS
1	Antihypertensive and vasodilator effects of methanolic and aqueous extracts of <i>Tribulus terrestris</i> in rats. <i>Journal of Ethnopharmacology</i> , 2006, 104, 351-355.	4.1	85
2	Synthesis and antibacterial activity of novel 5-(4-methyl-1H-1,2,3-triazole) methyl oxazolidinones. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 3217-3227.	5.5	82
3	Species prevalence and antibacterial resistance of enterococci isolated in Kuwait hospitals. <i>Journal of Medical Microbiology</i> , 2003, 52, 163-168.	1.8	46
4	Determination of linezolid in human plasma by LC-MS-MS. <i>Analyst</i> , The, 2001, 126, 609-614.	3.5	45
5	Synthesis and antibacterial activity of new N-linked 5-triazolymethyl oxazolidinones. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 4113-4123.	3.0	39
6	Structure-antibacterial activity of arylcarbonyl- and arylsulfonyl-piperazine 5-triazolymethyl oxazolidinones. <i>European Journal of Medicinal Chemistry</i> , 2007, 42, 214-225.	5.5	38
7	Synthesis, antibacterial and anticonvulsant evaluations of some cyclic enaminones. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 967-975.	5.5	34
8	Synthesis and structure-antibacterial activity of triazolyl oxazolidinones containing long chain acyl moiety. <i>European Journal of Medicinal Chemistry</i> , 2008, 43, 1095-1104.	5.5	30
9	Oxazolidinone antimicrobials: a patent review (2012-2015). <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 591-605.	5.0	29
10	Pleuromutilin antibacterial agents: patent review 2001 - 2006. <i>Expert Opinion on Therapeutic Patents</i> , 2007, 17, 429-435.	5.0	24
11	LC-MS/MS determination of Synercid® injections. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2003, 32, 1167-1174.	2.8	22
12	Synthesis and antibacterial activities of N-substituted-glycinyl 1H-1,2,3-triazolyl oxazolidinones. <i>European Journal of Medicinal Chemistry</i> , 2013, 66, 246-257.	5.5	22
13	Synthesis and biological evaluation of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives. <i>European Journal of Medicinal Chemistry</i> , 2015, 106, 120-131.	5.5	20
14	H2S donor GYY4137 ameliorates paclitaxel-induced neuropathic pain in mice. <i>Biomedicine and Pharmacotherapy</i> , 2020, 127, 110210.	5.6	20
15	LC-MS/MS Determination of Carbamazepine, Pindolol, and Theophylline in Human Serum. <i>Journal of Liquid Chromatography and Related Technologies</i> , 2003, 26, 1937-1957.	1.0	14
16	Synthesis, neuronal activity and mechanisms of action of halogenated enaminones. <i>European Journal of Medicinal Chemistry</i> , 2014, 76, 20-30.	5.5	13
17	A validated UPLC-MS/MS method for the analysis of linezolid and a novel oxazolidinone derivative (PH027) in plasma and its application to tissue distribution study in rabbits. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2017, 1040, 89-96.	2.3	13
18	Evaluation of Anticonvulsant Actions of Dibromophenyl Enaminones Using In Vitro and In Vivo Seizure Models. <i>PLoS ONE</i> , 2014, 9, e99770.	2.5	12

#	ARTICLE	IF	CITATIONS
19	Novel Actions of Oxazolidinones: In vitro Screening of a Triazoloxazolidinone for Anticonvulsant Activity. <i>Medical Principles and Practice</i> , 2013, 22, 340-345.	2.4	11
20	Evaluation of the monoamine oxidases inhibitory activity of a small series of 5-(azole)methyl oxazolidinones. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 71, 56-61.	4.0	11
21	Antiproliferative activity of a series of 5-(1H-1,2,3-triazolyl) methyl- and 5-acetamidomethyl-oxazolidinone derivatives. <i>Molecular Medicine Reports</i> , 2016, 13, 3311-3318.	2.4	9
22	Chemical Modification of Tazobactam. Synthesis of 2.BETA.-((4-Substituted)-1,2,3-triazol-1-yl)methyl Penicillanic Acid Sulfone Derivatives.. <i>Journal of Antibiotics</i> , 1995, 48, 1320-1329.	2.0	8
23	Synthesis and biological evaluation of penam sulfones as inhibitors of β -lactamases. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 2847-2858.	3.0	8
24	Antimycobacterial Activities of Novel 5-(1H-1,2,3-Triazolyl)Methyl Oxazolidinones. <i>Tuberculosis Research and Treatment</i> , 2012, 2012, 1-7.	0.6	8
25	Effects of Varied Substituents on the Antibacterial Activity of Triazolylmethyl Oxazolidinones. <i>Archiv Der Pharmazie</i> , 2012, 345, 790-803.	4.1	8
26	Antimycobacterial Activities of N-Substituted-Glyciny 1H-1,2,3-Triazolyl Oxazolidinones and Analytical Method Development and Validation for a Representative Compound. <i>Scientia Pharmaceutica</i> , 2017, 85, 34.	2.0	8
27	The Effect of Systematic Structural Modifications on the Antibacterial Activity of Novel Oxazolidinones. <i>Medicinal Chemistry</i> , 2011, 7, 45-55.	1.5	7
28	Comparative Pharmacokinetic Study for Linezolid and Two Novel Antibacterial Oxazolidinone Derivatives in Rabbits: Can Differences in the Pharmacokinetic Properties Explain the Discrepancies between Their In Vivo and In Vitro Antibacterial Activities?. <i>Pharmaceutics</i> , 2017, 9, 34.	4.5	7
29	A novel oxazolidinone derivative PH192 demonstrates anticonvulsant activity in vivo in rats and mice. <i>European Journal of Pharmaceutical Sciences</i> , 2019, 130, 21-26.	4.0	7
30	Synthesis and structure-activity relationships of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives as 5-lipoxygenase inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2020, 35, 1471-1482.	5.2	7
31	Determination Of Novel Antibacterial Triazolylmethyl Oxazolidinones Concentrations In Human Plasma By APCI-LC-MS: Application To Stability Study. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2008, 11, 22.	2.1	6
32	Studies on Penam Sulfones. I. Synthesis and .BETA.-Lactamase Inhibitory Activity of 2.BETA.-Alkoxy carbonyl Penicillanic Acid Sulfones.. <i>Journal of Antibiotics</i> , 1996, 49, 944-946.	2.0	5
33	Assessment of the Stability of Novel Antibacterial Triazolyl Oxazolidinones Using a Stability-Indicating High-Performance Liquid Chromatography Method. <i>Medical Principles and Practice</i> , 2011, 20, 51-59.	2.4	5
34	Antimicrobial activity and DNA/HSA interaction of fluorinated 3,6,9-trisubstituted acridines. <i>Chemical Papers</i> , 2020, 74, 2327-2337.	2.2	5
35	β -Lactamase inhibitors: a survey of the patent literature 2000 – 2004. <i>Expert Opinion on Therapeutic Patents</i> , 2006, 16, 319-331.	5.0	4
36	GY4137 attenuates functional impairment of corpus cavernosum and reduces fibrosis in rats with STZ-induced diabetes by inhibiting the TGF- β 1/Smad/CTGF pathway. <i>Biomedicine and Pharmacotherapy</i> , 2021, 138, 111486.	5.6	4

#	ARTICLE	IF	CITATIONS
37	Alleviation of impaired reactivity in the corpus cavernosum of STZ-diabetic rats by slow-release H2S donor GYY4137. <i>International Journal of Impotence Research</i> , 2019, 31, 111-118.	1.8	3
38	Anti-allergic, anti-asthmatic and anti-inflammatory effects of an oxazolidinone hydroxamic acid derivative (PH-251) – A novel dual inhibitor of 5-lipoxygenase and mast cell degranulation. <i>International Immunopharmacology</i> , 2022, 105, 108558.	3.8	3
39	Anti-progressive Effects of a Series of Glycinyln and Alaninyln Triazolyl-oxazolidinones on Kelly Neuroblastoma Cell Line. <i>Anticancer Research</i> , 2020, 40, 5125-5140.	1.1	2
40	Structure-Antibacterial Activity Relationships of N-Substituted-(d-/l-Alaninyln) 1H-1,2,3-Triazolylmethyl Oxazolidinones. <i>Scientia Pharmaceutica</i> , 2018, 86, 42.	2.0	1
41	Antibacterial agents: patent highlights July to December 2002. <i>Current Opinion in Investigational Drugs</i> , 2003, 4, 117-27.	2.3	1
42	5-Hydroxymethyl-oxazolidin-2-one antibacterials. <i>Expert Opinion on Therapeutic Patents</i> , 2009, 19, 529-540.	5.0	0
43	Development and Validation of Stability-Indicating Assay Method for a Novel Oxazolidinone (PH-192) with Anticonvulsant Activity by Using UHPLC-QToF-MS. <i>Molecules</i> , 2022, 27, 1090.	3.8	0
44	Antibacterial agents: patent highlights January to June 2002. <i>Current Opinion in Investigational Drugs</i> , 2002, 3, 1701-11.	2.3	0
45	Antibacterial agents: patent highlights January to June 2003. <i>Current Opinion in Investigational Drugs</i> , 2003, 4, 926-36.	2.3	0
46	Antibacterial agents: patent highlights January to June 2004. <i>Current Opinion in Investigational Drugs</i> , 2004, 5, 799-808.	2.3	0
47	Antibacterial agents: patent highlights January 2005 to June 2005. <i>Current Opinion in Investigational Drugs</i> , 2005, 6, 768-80.	2.3	0